The following items provide context. Where noted, timing, source status or applicability remains unresolved.
Review qualification: Historical/context only. First posting date and registry functionality milestone are unverified; do not treat this as a verified new in-window item.
Summary
Historical/context: CMS guidance dated October 29, 2026 explains federal IDR batching and bundled payments. Its first posting date is unverified; the guidance was captured November 1. CMS describes batching criteria for negotiations beginning on or after November 1, while a separate resubmission restriction depends on a later registry milestone.
What changed
In guidance dated October 29, CMS describes the federal No Surprises Act independent dispute resolution process and the criteria for combining qualified items and services into one batched payment determination. The guidance identifies four required elements: the same billing provider, provider group, facility or air-ambulance provider; the same plan or issuer required to make payment; items related to treatment of a similar condition under one of the specified methods; and the applicable service and negotiation timing rules. It distinguishes the same self-insured plan from the same issuer of fully insured coverage; a shared administrator alone is not the test. It explains the single-patient encounter, same or comparable service-code, and specified anesthesiology, radiology, pathology and laboratory code-range methods. Ordinarily, services must fall within the specified 30-business-day period following the earliest service date. Initiation ordinarily must occur in the four business days beginning on the first business day after open negotiation ends, subject to cooling-off exceptions and approved extensions. A batched dispute may contain no more than 50 line items: modifiers and anesthesia qualifying-circumstance codes functioning as modifiers do not count toward that limit, while traditional CPT add-on codes are separate line items and do count.
The guidance says the Departments announced the needed batching functionality would be available November 1, 2026, and that parties must apply the final-rule batching criteria to items and services whose open negotiation periods begin on or after that date. It separately says the final-rule bundling provisions applied from August 3, 2026. A bundled arrangement involves multiple items or services for a single patient represented by one service code, either billed that way or paid or denied initially under that code; it is distinct from simply grouping multiple lines. The guidance ties removal of the flexibility to resubmit incorrectly batched disputes to 120 days after the registry provisions become applicable, which occurs 90 business days after the Departments announce that registry functionality has become available. The underlying final rules and any later notices must be checked before stating an operative end date for that flexibility.
Why it matters
Out-of-network billing, dispute-resolution and revenue-cycle teams need to distinguish when negotiation began, whether proposed lines satisfy the same-party and similar-condition tests, and whether a submission is a batch or a bundled arrangement. Misgrouping can affect how a certified entity proceeds; the guidance does not itself establish that every disputed item qualifies for federal IDR.
Suggested action
Have the responsible billing and legal teams compare submission templates and intake checks with the final rule, CMS examples and current registry notices. Review service and negotiation dates, payer and provider identities, coding relationships and line counts before submitting a batch; separately monitor the registry milestone for any change to resubmission handling.
Sources
FDA published an October 30 final order codifying a Class II classification with special controls for a spinal-imaging system for neuraxial procedures. The order identifies an earlier January 19, 2024 classification date. Publication is not a new individual device clearance or proof that a particular procedure is safe.
Suggested owner and action: Clinical engineering and relevant anesthesia teams can compare the order’s device type and special controls with their actual equipment and procurement questions; the order is not a new clearance of a particular device.
FDA classification order
FDA published an October 30 final order codifying a Class II classification with special controls for an over-the-counter sleep-apnea risk-assessment device type, identifying an earlier February 6, 2024 classification date. The identified device type is not a standalone diagnosis, a substitute for polysomnography or an apnea monitor. This is not a new individual device clearance.
Suggested owner and action: Sleep-medicine and patient-education teams can assess whether the distinction between risk assessment and diagnosis is clear in their materials; the classification does not replace an individual clinical assessment.
FDA classification order
FDA published an October 30 final order codifying a Class II classification with special controls for prescription software that provides an adjunctive second read after a suspicious skin lesion is identified. The order identifies an earlier January 12, 2024 classification date and describes use as an adjunctive second read for physicians not trained in the clinical diagnosis and management of skin cancer. This is not a new individual device clearance.
Suggested owner and action: Dermatology, clinical informatics and procurement teams can compare the device type and labeled scope with actual intended use before making workflow decisions.
FDA classification order
FDA published an October 30 final order codifying a Class II classification with special controls for prescription radiology software providing adjunctive information in a fibrotic-lung referral pathway. The order identifies an earlier January 12, 2024 classification date. It is not a standalone diagnosis or a new individual device clearance.
Suggested owner and action: Radiology and clinical informatics teams can review intended use and referral workflows for any relevant product, recognizing that the classification describes adjunctive information rather than a standalone diagnosis.
FDA classification order
FDA issued three distinct product-safety notifications during the reporting window. These are medication-reconciliation and patient-safety context, not a new provider rule, recall designation or mandatory reporting change.
- RX7 Articulaciones, October 28: FDA identified diclofenac and dexamethasone that were absent from the label. FDA notification
- Ort-Flx, October 28: FDA identified unlisted diclofenac, dexamethasone and methocarbamol. FDA notification
- Demograss Premier, October 27: FDA identified unlisted phenolphthalein. FDA notification
FDA advises against purchasing or using these products. People taking RX7 Articulaciones or Ort-Flx should promptly consult a healthcare professional about discontinuing safely, because corticosteroid withdrawal requires professional assessment. This safe-discontinuation instruction is specific to those two steroid-containing products.
Suggested owner and action: Pharmacy and clinical teams can ask about these named products during medication reconciliation, consult the current FDA notices and address possible use with the treating clinician. The three notices describe different products and ingredients; their instructions should not be combined into a single treatment recommendation.